{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Su J"],"funding":["Natural Science Foundation of Fujian Province","Fujian Provincial Regional Development Project","MOST | National Natural Science Foundation of China (NSFC)","Natural Science Foundation of Fujian Province (Fujian Natural Science Foundation)","MOST | National Natural Science Foundation of China"],"pagination":["e0052124"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11237498"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["15(6)"],"pubmed_abstract":["Despite its high mortality, specific and effective drugs for sepsis are lacking. Decoy receptor 3 (DcR3) is a potential biomarker for the progression of inflammatory diseases. The recombinant human DcR3-Fc chimera protein (DcR3.Fc) suppresses inflammatory responses in mice with sepsis, which is critical for improving survival. The Fc region can exert detrimental effects on the patient, and endogenous peptides are highly conducive to clinical application. However, the mechanisms underlying the effects of DcR3 on sepsis are unknown. Herein, we aimed to demonstrate that DcR3 may be beneficial in treating sepsis and investigated its mechanism of action. Recombinant DcR3 was obtained <i>in vitro</i>. Postoperative DcR3 treatment was performed in mouse models of lipopolysaccharide- and cecal lig"],"journal":["mBio"],"pubmed_title":["Inhibitory mechanisms of decoy receptor 3 in cecal ligation and puncture-induced sepsis."],"pmcid":["PMC11237498"],"funding_grant_id":["81901243","82202906","2021J01204","81803547","2021N3005"],"pubmed_authors":["Chen Q","Feng Z","Chen K","Chen L","Tong Z","Su J","Li R","Ye Z","Lin B","Zhang Y","Chen W","Wu S","Zhou F","Guan B","Yu X"],"additional_accession":[]},"is_claimable":false,"name":"Inhibitory mechanisms of decoy receptor 3 in cecal ligation and puncture-induced sepsis.","description":"Despite its high mortality, specific and effective drugs for sepsis are lacking. Decoy receptor 3 (DcR3) is a potential biomarker for the progression of inflammatory diseases. The recombinant human DcR3-Fc chimera protein (DcR3.Fc) suppresses inflammatory responses in mice with sepsis, which is critical for improving survival. The Fc region can exert detrimental effects on the patient, and endogenous peptides are highly conducive to clinical application. However, the mechanisms underlying the effects of DcR3 on sepsis are unknown. Herein, we aimed to demonstrate that DcR3 may be beneficial in treating sepsis and investigated its mechanism of action. Recombinant DcR3 was obtained <i>in vitro</i>. Postoperative DcR3 treatment was performed in mouse models of lipopolysaccharide- and cecal lig","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Jun","modification":"2025-04-19T01:06:43.899Z","creation":"2025-04-07T12:06:03.112Z"},"accession":"S-EPMC11237498","cross_references":{"pubmed":["38700314"],"doi":["10.1128/mbio.00521-24"]}}